The study drug (BMN 331) is an investigational gene therapy for patients with hereditary angioedema (HAE) designed to introduce many copies of the SERPING1 gene into the liver and to see if it can make C1-INH protein. The study drug is given as a single intravenous (IV) infusion and is designed to target liver cells.
Investigational means that the study drug has not been approved for use by authorities that regulate new medicines, such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) and has not been determined to be safe or effective. The study drug can only be used in clinical research studies.
Gene therapy is being researched as a method of using genetic material to potentially treat or prevent disease and other conditions. For this investigational gene therapy, a neutralized adeno-associated virus (AAV5) is used as the vehicle that is designed to transfer a functional gene to the liver cells. The AAV vector, or viral shell, is neutralized to not cause illness since most of the viral components of the vector have been removed and replaced with the functional gene.
The visual below explains what the study drug is designed to do and part of what researchers will be looking at in the HAErmony-1 study:
With this investigational gene therapy, there is no gene replacement or editing, just introducing the functional gene into the body. The functional gene is not intended to be passed down to future generations.
Gene Therapy FAQsNo, HAErmony-1 is a Phase 1/2 study, where the study drug has not been researched in people. The study drug has been studied in mice and non-human primates (monkeys) where it showed production of C1-INH protein. The method using AAV5 vectors to deliver functional genes has been tested in clinical trials for other genes and diseases.